about
Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trialTiclopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) TrialRisk of stroke associated with abciximab among patients undergoing percutaneous coronary interventionAbciximab readministration: results of the ReoPro Readministration RegistryFirst experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluationIs clopidogrel cardiovascular medicine's double-edged sword?Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary interventionLong-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trialBivalirudin for patients with acute coronary syndromesResults of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trialACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial InfarctionAntithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-IIPre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer.Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency.Final results of the ReoPro readministration registry.Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.Smoking, clopidogrel, and mortality in patients with established cardiovascular disease.Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends.2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart AssociaThrombin-receptor antagonist vorapaxar in acute coronary syndromes.2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of CardiolCardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to RevPioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization andOutcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization
P50
Q28168414-6C6201F7-73BD-4642-A769-570283AD7451Q28170627-6131247A-7E3F-40FC-958A-099E0608CC19Q28176922-83AA0406-7C3E-4DA7-94DD-9CD1F9A7C80BQ28186016-3C358830-E0FB-4AB5-AE0A-2A25D3B18556Q28188149-354E87A5-CA50-44DA-9ABF-A04033195D93Q28193038-BE2E0C9A-960C-46DD-8148-E9B629156835Q28196334-090F60B3-78B3-4F73-8175-C406F66F30E1Q28210485-E7BDC236-1997-4099-80E9-752257A848DEQ28210574-CE1063C4-567E-4C67-9D62-BE6BCE45AF0BQ28210982-AB5CDDE7-9C43-4D7B-9DAD-A692FE4C916BQ28220325-A10B009E-4EB6-428A-9A55-BD9C754DBB00Q28240355-89277611-F297-4AA7-8E6B-30D332F71632Q28284905-3F5D80E8-9B82-472A-A34C-064B8D9BA17DQ28296568-5DADD61E-7D6C-4AB1-AB9A-9F101286633DQ30276130-29E42F5B-2285-48C1-B327-CF540DD92B7FQ30767089-94B4201E-3985-4613-BC01-688FE2525408Q30983150-3C1D17B0-320C-4221-90F2-95D9F90CD770Q32055057-F23280C4-DE03-450F-A637-EDA58EEA7D75Q32076709-9AD6710F-B00B-49F6-97D0-C9202A0A320FQ33179615-5733A02F-5E50-4461-9693-4A9F85A00397Q33329110-67A994C4-D651-453C-BD87-E35165397EB9Q33332961-529385D1-66A0-4DD8-8479-214B95CA4BC0Q33342386-485815DE-E074-4853-826F-01EA5A92BC9AQ33360394-889FCBE4-5804-4B03-B7D7-7D3B648CDDF5Q33363549-FED06E6A-11C4-4CBD-AE5C-513AB8B23C87Q33621896-233FD138-BC05-439B-BCC6-1EAE63532410Q33750461-06910F4F-23BD-4D53-89D0-061906620C74Q33841478-94FBF6E4-BC53-4F0B-94BB-E35229416987Q33887755-DDFF6532-FFFD-4744-8EA1-38702AD0ED3EQ33904627-CA224913-25BB-42D7-AF99-8070DBDF6EAAQ34174388-CD88627E-C2F1-45E6-B079-3CDB3AF57807Q34231934-62122945-B09E-48E8-963C-09CD4724948DQ34288425-F6DDE39C-9F70-48BB-8CF6-C5BCCA85B6D7Q34547253-D838AE45-446C-46C0-9D6E-202B2284454FQ34659902-DC653B6C-6157-41B1-B502-E9744A795417Q34686089-969B416E-2AF7-42B5-9EB4-1AD7DB82939BQ34766176-5A890F26-3EEE-4266-815B-ACB6E28DC686Q34775547-6363CFCC-6D44-4884-BFE0-4F76EE1E1790Q34982415-F784BB18-5B45-4788-8383-883DE1D4E048Q34982591-AE0281B7-D598-4E6F-A6DF-8C4852EB92E7
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
A Michael Lincoff
@ast
A Michael Lincoff
@en
A Michael Lincoff
@es
A Michael Lincoff
@nl
type
label
A Michael Lincoff
@ast
A Michael Lincoff
@en
A Michael Lincoff
@es
A Michael Lincoff
@nl
prefLabel
A Michael Lincoff
@ast
A Michael Lincoff
@en
A Michael Lincoff
@es
A Michael Lincoff
@nl
P106
P108
P31
P496
0000-0001-8175-2121